Loading company
Evolus, Inc.
EOLS · Nasdaq · ·
Next earnings: November 4, 2026
$7.99+0.4%Sep 29 close
- 1M
- -10.0%
- 6M
- +102.8%
- 1Y
- +30.1%
- 5Y
- +2.4%
Evolus, Inc. is the 39th largest of 78 graded companies. Showing 5 of them, including EOLS itself. 6 more are in this industry but have no grade yet, so they are left out rather than shown blank.
| Company | Grade | Market value | Revenue | Profit margin | Free cash flow | Price to earnings |
|---|---|---|---|---|---|---|
| Teva Pharmaceutical Industries LimitedTEVA | A | $46.3B | $17.3B | 4.1% | $1.3B | 66.29 |
| Haleon plcHLN | B+ | $40.6B | $14.6B | 15.1% | $3.1B | 18.48 |
| Takeda Pharmaceutical Company LimitedTAK | B | $29.7B | $28.7B | -3.4% | $5.5B | 43.22 |
| Zoetis Inc.ZTS | A+ | $29B | $9.5B | 27.5% | $2.3B | 11.58 |
| Evolus, Inc.EOLS | B | $527.7M | $316.5M | -10.8% | -$18.3M | — |
A blank price-to-earnings means a loss, not a missing figure — the ratio has no meaning when there are no earnings to divide by, and printing a negative one would make the least profitable company look the cheapest.
Grades are trailing twelve months from each company’s own SEC filings, so they move only when a company files. Every column is computed by the same code that graded Evolus, Inc. on the overview — nothing here comes from a data vendor’s own ratios.
Industry membership is not a judgement about how similar two businesses are. It groups companies by what they are classified as, which is a starting point for comparison rather than a claim that they compete.
73 more drug manufacturers specialty and generic companies
Graded on the same five checks, from their own SEC filings.
EOLS · Nasdaq · ·
Next earnings: November 4, 2026
$7.99+0.4%Sep 29 close